Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
14 November 2022 - 10:11PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
November 4, 2022
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Form 20-F [X] |
Form 40-F [ ] |
Indicate by check mark whether the registrant by furnishing the information contained
in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
If “Yes” is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g-32(b):82-________
Novo
Nordisk A/S purchases B shares worth DKK 3,582 million from Novo Holdings A/S under the 2022 share repurchase programme
Bagsværd,
Denmark, 04 November 2022 – Today, Novo Nordisk A/S has entered into an agreement to purchase 4,207,500 B shares of
DKK 0.20 at a value of DKK 3,582 million from Novo Holdings A/S. The transaction is part of Novo Nordisk A/S’ 2022 share repurchase
programme of up to a total of DKK 24 billion to be executed during a 12-month period beginning 2 February 2022. The transaction price
is DKK 851.26 per share and has been calculated as the three-day volume weighted average market price from 2 November 2022 to 4 November
2022 in the open window following the announcement of Novo Nordisk A/S’ quarterly financial results.
Prior to the sale of B shares, Novo Holdings A/S’
ownership of Novo Nordisk A/S was 28.2% of the share capital and 77.0% of the votes. Following the transaction, Novo Holdings A/S owns
537,436,000 A shares of DKK 0.20 and 102,104,000 B shares of DKK 0.20, corresponding to 28.1% of the capital and 76.9% of the votes in
Novo Nordisk A/S.
The transaction is in line
with the announcement on 2 November that Novo Holdings A/S intends to maintain its ownership of Novo Nordisk A/S’ share
capital around 28%.
With the transactions stated above, Novo Nordisk A/S owns
a total of 27,443,142 B shares of DKK 0.20, corresponding to 1.2% of the share capital, as treasury shares. The total number of A and
B shares in the company is 2,280,000,000 of DKK 0.20 including treasury shares.
About Novo Holdings A/S
Novo Holdings A/S
is a private limited liability company wholly owned by the Novo Nordisk Foundation. It is the holding company of the Novo Group,
comprising Novo Nordisk A/S and Novozymes A/S, and is responsible for managing the Novo Nordisk Foundation’s assets. Novo
Holdings is recognized as a leading international life science investor, with a focus on creating long-term value. As a life science
investor, Novo Holdings provides seed and venture capital to development-stage companies and takes significant ownership positions
in growth and well-established companies. Novo Holdings also manages a broad portfolio of diversified financial assets. Further
information: www.novoholdings.dk.
About Novo Nordisk A/S
Novo Nordisk is a leading
global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other
serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding
access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 53,000 people in 80 countries
and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed
on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and YouTube.
Contact for further information
Media: |
|
Ambre
Brown Morley
+45
3079 9289
abmo@novonordisk.com |
Natalia
Salomao Abrahao (US)
+1
848 304 1027
niaa@novonordisk.com |
|
|
Investors: |
|
Daniel
Muusmann Bohsen
+45
3075 2175
dabo@novonordisk.com |
Jacob
Martin Wiborg Rode
+45
3075 5956
jrde@novonordisk.com |
|
|
David
Heiberg Landsted
+45
3077 6915
dhel@novonordisk.com |
Mark
Joseph Root (US)
+1
848 213 3219
mjhr@novonordisk.com |
Novo Nordisk A/S
Investor Relations |
Novo Allé
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
|
|
Company announcement No 81 / 2022 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: November 4, 2022 |
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer |
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Jul 2023 to Jul 2024